

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

December 15, 2011

615 Howerton Court, 2nd floor

Jefferson City, MO 65109

Committee Members Present

Conrad Balcer, D.O.
Stephen Calloway, RPh
Laine Young-Walker, M.D. – via phone
Pat Bryant, PharmD – via video conference
Morgan Sperry, PharmD, (alternate) – via video conference

Committee Members Absent:

Gene Forrester, RPh

MO HealthNet Staff Present:

Rhonda Driver, RPh, Director of Pharmacy
Samar Muzaffar, Medical Director
Mark Roaseau, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal Manager
Jayne Zemmer, Program Manager
Allison Lauf, RN
Jenna Twehus, RN
Angela Wilson, Unit Supervisor
Steve Tatlow, Program Development Specialist
Nancy Nikodym, Correspondence and Information Specialist
Tasia Roberts, Clerical
Chrissy Wilson, Clerical

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS
Josh Moore, ACS

Others Attending:

Eric Blake, Merck	Mike Kloos, Pfizer	Bruce Valentine, Acorda	Gary Detmer, Taro
Dave Sproat, BMS	Lon Lowry, Novartis	Annie Palmer, Taro	Grant Cale, Bristol Meyers Squibb
Brian Hutchinson, Acorda	David Bregman MD, Luitpold	Michelle Arledge, J&J	Scott Edelhauser, Alcon
Jim Bauman, Pfizer	Dean Groth, Pfizer	Terri Hurleym Astra Zeneca	Berend Koops, Merck
Carol Curtis, Astra Zeneca			

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Drug Prior Authorization Committee
December 15, 2011

Welcome, Introductions and Opening Remarks	Rhonda Driver, RPh, Director of Pharmacy called the meeting to order. Stephen Calloway, acting chairperson asked for introductions of guests and new staff to MHD. Samar Muzaffar, Medical Director was introduced and gave a brief description of her new role within the division. Clinical Services Unit staff Steve Tatlow, a new Program Development Specialist, was also introduced.
Minutes Approval	Minutes of the September 15, 2011 meeting were reviewed and approved as submitted. (See Roll Call Vote)
Pharmacy Program/Budget Update	Ms. Driver announced MO HealthNet Division is finally getting settled into our new location. Instructions were given to check the Calendar of Events for future meeting locations. Andrew Haslag reported that the Department submitted its budget request on or about October 1, 2011. There have been various reports on the anticipated shortfall, so a tight budget year is anticipated. The Governor will make his State of the State address on January 17, 2012, so this will shed some light on the budget from his perspective.
DUR Report	Mark Roaseau reported the DUR Board reviewed, and concurred with the recommendations made by the Drug Prior Authorization (PA) Committee in September and October will be scheduled for implementation.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings. Implementation of these edits should be October 6 th . Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	
New Drug Review	<p>Discussion – A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending.</p> <ul style="list-style-type: none"> • Public Hearing – Theresa Hurley RN, with AstraZeneca presented studies for the product Brilinta. • Michelle Arledge with Janssen HECOR presented studies for the product Xarelto. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edit (CE) Annual Review:	Products under review this quarter are currently on the PDL with contracts expiring in September 2011. Recommended changes to the current edits were bolded on the criteria documents presented (See Meeting Packet), for easy identification.
Vivitrol-Clinical Edit	<ul style="list-style-type: none"> • Discussion –Ms. Driver reviewed the criteria document noting additions to the criteria originally recommended by the Department of Mental Health, including which provider types are able to prescribe the product and clarification on what constitutes an adequate trial of oral naltrexone. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
SNRI-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, noting additions to the approval diagnoses to include Osteoarthritis and Lumbago. • Public Hearing-No comments were entered.

	<ul style="list-style-type: none"> • Decision –The Committee voted to accept this edit as presented. (See Roll Call Vote)
Zostavax-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, noting the age range for therapy is now 50 years and older. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Amitiza-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document noting the addition of chronic idiopathic constipation to the approval diagnoses. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Ampyra-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the existing criteria document. There were no edit change recommendations from MHD. Manufacturer requested annual review • Public Hearing- Brian Hutchinson, Regional Scientific Manager with Accordia gave a presentation regarding Ampyra. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Tetracyclines-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit with the addition of criteria arm for use of Demeclocycline as first-line for treatment of SIADH. (See Roll Call Vote)
Topical Steroids-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting the list was voluminous and difficult to sort through. • Public Hearing- Annie Palmer, Professional Medical Representative with Taro Pharmaceuticals presented Topicort. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
NSAIDs-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing- David Bregman, M.D., PhD, Medical Director, Luitpold Pharmaceuticals, gave a presentation regarding Sprix. Michael Kloos, Pharm D, Medical Outcomes Specialist and Jim Baumann, R.Ph, Senior Account Manager, with Pfizer, gave a presentation on Flector. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Cough & Cold Preparations-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting this too was a list that was voluminous and difficult to sort through. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit with the recommendation to add the missing narcotic-containing preparations. (See Roll Call Vote)
Preferred Drug List Discussion/Therapeutic Classes	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This meeting will be an annual review of products with contracts expiring December 31, 2011. This handout was also provided to all attendees and will be

	posted to the Division's web page.
ACS Update	Jennifer Kemp-Cornelius, PharmD reviewed the regression analysis reports for the <i>Atypical Antipsychotic Edit, ADHD Edit, SSRI Edit and SNRI edit</i> . Discussion ensued surrounding how these analysis' could be extrapolated to fiscal savings that could be attributed to the implementation of the edits. ACS and MHD will continue to refine the analysis reports in order to quantify cost avoidance due to these edits. An additional discussion ensued regarding the upcoming implementation of the <i>Short Acting Narcotic Edits</i> . Ms. Driver and Ms. Kemp-Cornelius reported that the edits will be implemented soon. ACS and MHD wanted to be certain that the algorithms were written in a way that would curb inappropriate use of short acting narcotic agents without denying access to care for those patients with legitimate acute pain issues. Members agreed that a way to allow a small quantity of medication in certain circumstances to allow the primary physician time to obtain a PA if needed was an appropriate course of action.
Program Utilization: Top 25 Drugs by Cost	No report was available for this meeting.
Call Center Statistics/ CyberAccess Reports	A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics for November 2011 were included. Cyber Access Active User Counts and Logging Information reports detailing activity through December 2011 were shared.
Adjourn	The meeting was adjourned at approximately 1:30pm. The next meeting of the Drug PA Committee is scheduled for March 22, 2012 and is expected to be held at 615 Howerton Court. Attendees were advised to check the calendar of events on the MHD website for meeting location changes over the next few months as MHD works to find appropriate meeting space which is not available at the Howerton Court location. (See attached roll call)

Roll Call Votes – December 15, 2011

Member		New Drug Review					
	Minutes		Vivitrol	SNRI	Zostavax	Amitiza	Ampyra
Conrad Balcer, D.O.	Y	M	Y	M	M	M	M
Pat Bryant, Pharm.D.	S	S	S	S	S	S	S
Steven Calloway, R. Ph	M	Y	M	Y	Y	Y	Y
Gene Forrester, R. Ph.	A	A	A	A	A	A	A
Laine Young-Walker, M.D.	Y	N/A	N/A	N/A	N/A	N/A	N/A

Member		Topical Steroids		Cough & Cold Preparations	
	Tetracyclines		NSAIDs		Adjourn
Conrad Balcer, D.O.	M	M	M	M	M
Pat Bryant, Pharm.D.	S	S	S	S	S
Steven Calloway, R. Ph	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	A	A	A	A	A
Laine Young-Walker, M.D.	N/A	N/A	N/A	N/A	N/A